Jan 7, 2021
https://pubmed.ncbi.nlm.nih.gov/33411811/
Apr 27, 2018
FOR IMMEDIATE RELEASE Potential Hearing Loss Drug Featured in The Scientist Otologic Pharmaceutics, in collaboration with the Hough Ear Institute, has developed a new drug that could restore hearing Through siRNA therapy, OPI/HEI scientists are able to regrow lost or...
Oct 1, 2017
Only Funded Application Among 73 Applicants Otologic Pharmaceutics, Inc. (OPI), in alliance with The Hough Ear Institute (HEI), announces the award of a Congressionally Directed Medical Research Programs (CDMRP) grant from the Department of Defense. The grant of $1.9...
Dec 1, 2015
Otologic Pharmaceutics, Inc. (OPI), a development-stage biopharmaceutical company committed to developing and commercializing novel pharmacological solutions and approaches to treat hearing disorders, announced the successful completion of single and multi-dose Phase...
Apr 3, 2014
Financing to Support Entry of OPI’s Lead Product Candidate – NHPN-1010 – into Clinical Testing First Half of 2014 OKLAHOMA CITY, April 3, 2014 /PRNewswire/ — Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, Inc.,...
